Robert A. Fenstermaker, MD

Dr. Fenstermaker is a co-inventor of the survivin vaccine technology on which MimiVax was founded. He joined Roswell Park Comprehensive Cancer Center in 1995, became Chairman of the Department of Neurosurgery in 1997, and was appointed Co-Director of the Gamma Knife Center when it opened in 1998.

He earned his medical degree at Northeast Ohio Medical University (previously known as Northeastern Ohio Universities College of Medicine) in 1981. Following residency training in neurosurgery at University Hospitals of Cleveland in 1986, he completed a fellowship in pharmacology and neurological surgery in 1987 and an NIH postdoctoral fellowship in biochemistry in 1989, both at Case Western Reserve University School of Medicine in Cleveland, Ohio. Dr. Fenstermaker is licensed to practice medicine in New York and is certified by the American Board of Neurological Surgery (1991). He is also Director of Neurosurgical Oncology and Professor of Neurosurgery at the University at Buffalo School of Medicine and Biomedical Sciences.

Dr. Fenstermaker is a member of the American Association of Neurological Surgeons, Congress of Neurological Surgeons, American College of Surgeons, Society for Neuro-Oncology, Gamma Knife Society, American Association for Cancer Research, and American Medical Association. He currently serves on the CNS Tumor Guidelines Panel of the National Comprehensive Cancer Network. Dr. Fenstermaker has co-authored more than 150 journal articles, book chapters and abstracts, has reviewed for leading cancer and neurosurgical journals, and has presented his research at numerous national and international meetings.